UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

Kidney international, 2019-07, Vol.96 (1), p.104-116

2019

Volltextzugriff (PDF)

Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus

Journal of Virology, 2009-12, Vol.83 (23), p.12473-12482

2009

Volltextzugriff (PDF)

A broadly neutralizing human monoclonal antibody is effective against H7N9

Proceedings of the National Academy of Sciences - PNAS, 2015-09, Vol.112 (35), p.10890-10895

2015

Volltextzugriff (PDF)

Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study

Antiviral research, 2020-12, Vol.184, p.104763-104763, Article 104763

2020

Volltextzugriff (PDF)

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2118-2131

2016

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants

Clinical pharmacology in drug development, 2023-12, Vol.12 (12), p.1211-1220

2023

Volltextzugriff (PDF)

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

EBioMedicine, 2016-03, Vol.5 (C), p.147-155

2016

Volltextzugriff (PDF)

Identification of a Human Monoclonal Antibody To Replace Equine Diphtheria Antitoxin for Treatment of Diphtheria Intoxication

Infection and Immunity, 2013-11, Vol.81 (11), p.3992-4000

2013

Volltextzugriff (PDF)

Reimaging space through anthropology, architecture and animation

Animation practice, process & production, 2023-06, Vol.12 (1), p.59-81

2023

Volltextzugriff (PDF)

G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates

Antiviral research, 2011-08, Vol.91 (2), p.187-194

2011

Volltextzugriff (PDF)

Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates

Vaccine, 2007-04, Vol.25 (15), p.2800-2810

2007

Volltextzugriff (PDF)

Subcutaneous VIS649, an APRIL-Neutralizing Antibody: Preliminary Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of VIS649-102, a Phase 1, Single Ascending Dose Study in Healthy Volunteers: PO2024

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.621-622

2021

Volltextzugriff (PDF)

MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

MO283IMPACT OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, ON TETANUS- AND DIPHTHERIA-TOXOID VACCINATION-ELICITED IMMUNE RESPONSES IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

The New England journal of medicine, 2010-01, Vol.362 (3), p.197-205

2010

Volltextzugriff (PDF)

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

EBioMedicine, 2019-02, Vol.40, p.574-582

2019

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers

Kidney international reports, 2022-05, Vol.7 (5), p.993-1003

2022

Volltextzugriff (PDF)

Experiences of a clinical leadership programme and its subsequent impact : a constructivist inquiry

Sloan, Susan

2019

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG 2 Monoclonal Antibody, in Healthy Volunteers

Kidney international reports, 2022-05, Vol.7 (5), p.993

2022

Volltextzugriff (PDF)

Evaluation of Alternate Patient Education Methods Regarding Treatment-Related Side Effects in Preparation for Radiation Therapy

Journal of medical imaging and radiation sciences, 2020-09, Vol.51 (3), p.S16-S16

2020

Volltextzugriff (PDF)

Anti-Influenza Antibody VIS410 Targets a Broadly Conserved Epitope on Hemagglutinin

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Recombinant Insulin-Like Growth Factor (IGF)-I Treatment in Short Children with Low IGF-I Levels: First-Year Results from a Randomized Clinical Trial

The journal of clinical endocrinology and metabolism, 2010-02, Vol.95 (2), p.611-619

2010

Volltextzugriff (PDF)

Abstract B103: Time for a change in breast cancer screening? A survey of female physicians’ perception of 2009 USPSTF guidelines on breast cancer screening

Cancer epidemiology, biomarkers & prevention, 2010-10, Vol.19 (10_Supplement), p.B103-B103

2010

Volltextzugriff (PDF)

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled studyResearch in context

EBioMedicine, 2019-02, Vol.40, p.574-582

2019

Volltextzugriff (PDF)

Optic Neuritis as the Initial Presentation in an Atypical Multiple Sclerosis Patient

Optometry (Saint Louis, Mo.), 2011-06, Vol.82 (6), p.369-370

2011

Volltextzugriff (PDF)

1 – 25 von 522

Suche als RSS-Feed

Aktive Filter

PublikationsformBerichte

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(351)
Mit Volltextzugriff
(436)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(520)
Japanisch
(47)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus

A broadly neutralizing human monoclonal antibody is effective against H7N9

Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome

Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

Identification of a Human Monoclonal Antibody To Replace Equine Diphtheria Antitoxin for Treatment of Diphtheria Intoxication

Reimaging space through anthropology, architecture and animation

G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates

Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates

Subcutaneous VIS649, an APRIL-Neutralizing Antibody: Preliminary Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of VIS649-102, a Phase 1, Single Ascending Dose Study in Healthy Volunteers: PO2024

MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY

MO283IMPACT OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, ON TETANUS- AND DIPHTHERIA-TOXOID VACCINATION-ELICITED IMMUNE RESPONSES IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers

Experiences of a clinical leadership programme and its subsequent impact : a constructivist inquiry

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG 2 Monoclonal Antibody, in Healthy Volunteers

Evaluation of Alternate Patient Education Methods Regarding Treatment-Related Side Effects in Preparation for Radiation Therapy

Anti-Influenza Antibody VIS410 Targets a Broadly Conserved Epitope on Hemagglutinin

Recombinant Insulin-Like Growth Factor (IGF)-I Treatment in Short Children with Low IGF-I Levels: First-Year Results from a Randomized Clinical Trial

Abstract B103: Time for a change in breast cancer screening? A survey of female physicians’ perception of 2009 USPSTF guidelines on breast cancer screening

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled studyResearch in context

Optic Neuritis as the Initial Presentation in an Atypical Multiple Sclerosis Patient

Aktive Filter

Suchergebnisse filtern